.svg){kind=small}
Driving innovation
in clinical research
.png)
At the forefront of drug evolution
Leading the way in First-in-Human studies with a variety of patient populations.
Take your asset from First-in-Human to Proof of Concept in under one year with our specialist services.
Take your asset from First-in-Human to Proof of Concept in under one year with our specialist services.
Thorough QT Studies
.svg)
Take your asset from FIH to POC in under one year using our specialist services.
-min.jpg)
We are Richmond Pharmacology.
We are committed to advancing science and driving innovations in drug development.
We reduce drug development timelines using knowledge and expertise accumulated from over 500 clinical trials.
We reduce drug development timelines using knowledge and expertise accumulated from over 500 clinical trials.
Work with us
We work with leading genetic engineering organisations, top 10 pharma companies and dynamic biotechs to assess the safety and efficacy of new therapeutics.
By working with us, you will gain a research partner who can expedite your study start up, enable fast decisions and reduce your drug development timelines.
-min.jpg)
.jpg)
Latest news
リッチモンド社、Beam Therapeuticsと共にα1アンチトリプシン欠乏症（AATD）の画期的な試験を実施
April 1, 2025
リッチモンドは、Beam Therapeutics が実施中の第1/2相試験において、α1アンチトリプシン欠乏症（AATD）の新たな治療法候補に関する最初の3つの用量レベルの予備的結果が得られたことを発表
Read moreリッチモンド、サステナビリティ・アクセラレータープログラムを通じてESGへの取り組みを強化
March 31, 2025
私たちは、責任ある持続可能なビジネス成長を促進するために、環境・社会・ガバナンス（ESG）の原則を臨床研究業務に組み込むことに取り組んでいます。
Read moreEvents
CRISPR Medicine 2025: Unlocking Gene-Editing Potential
April 7–11
Exploring advancements shaping the future of healthcare.
View event
